Knowledge about CD38-targeting strategies and mechanisms of resistance from these studies in myeloma may prove useful as researchers in the solid tumor field attempt to apply anti-CD38 therapeutic strategies especially for tumor types which have shown to have aberrant and dynamic CD38 activity, which will be described in the next section. The gene discussed is CD38; the disease is plasma cell myeloma.